What Is Diabetic Macular Edema?
Diabetic macular edema (DME) is a complication of diabetic eye disease that occurs when fluid builds up in the macula, the central portion of the retina responsible for sharp, detailed vision.
DME develops when damaged retinal blood vessels leak fluid into the macula, causing swelling that can affect central vision. It may occur at any stage of diabetic retinopathy and is one of the leading causes of vision loss in individuals with diabetes.
Early diagnosis and ongoing monitoring are important to help protect vision and manage disease progression.
Common Symptoms
Symptoms of diabetic macular edema may include:
Blurred or distorted central vision
Difficulty reading or focusing on details
Colors appearing faded or washed out
Dark or blank spots in central vision
Fluctuating vision changes
Difficulty recognizing faces
Some patients may experience gradual changes, while others notice more sudden visual disturbances.
Why Clinical Trials Matter
Clinical trials for diabetic macular edema help researchers study new therapies and treatment strategies aimed at reducing retinal swelling, preserving vision, and improving long-term outcomes.
Research studies may evaluate investigational medications, longer-lasting treatment options, imaging technologies, or novel approaches to diabetic retinal disease management. Participation in clinical research contributes to the advancement of future care options for patients living with DME.
Each study has specific eligibility requirements, and participation is always voluntary.
Current Research
Current Diabetic Macular Edema Studies
Study Name
A study in people with diabetic macular edema to test how well different doses of BI 3812465 are tolerated
Sponsor
Boehringer Ingelheim
Study Details
A first-in-human, open-label (Part 1), randomized (Part 2), Phase I/IIa trial to study safety and tolerability of multiple rising intravitreal doses of BI 3812465 in patients with center-involved diabetic macular edema
Who Can Participate
Participants must be 18 years or older with a confirmed diagnosis of Center-Involved Diabetic Macular Edema.
Study Name
An Evaluation of the Clinical Usability of the SCD411 Prefilled Syringe as a Proposed Biosimilar to US-licensed Eylea®
Sponsor
Sam Chun Dang
Study Details
This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), or Diabetic Retinopathy (DR)
Who Can Participate
Participants must be 18 years or older with a confirmed diagnosis of neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, or Diabetic Retinopathy (uni- or bilateral).